Get the Stockscreener App
21.94
2.36%
0.35
After Hours:
21.94
Forte Biosciences Inc stock is traded at $21.94, with a volume of 203.73K.
It is up +2.36% in the last 24 hours and down -19.49% over the past month.
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
See More
Previous Close:
$21.59
Open:
$21.87
24h Volume:
203.73K
Relative Volume:
0.73
Market Cap:
$449.31M
Revenue:
-
Net Income/Loss:
$-69.38M
P/E Ratio:
-4.1875
EPS:
-5.2394
Net Cash Flow:
$-51.00M
1W Performance:
+10.11%
1M Performance:
-19.49%
6M Performance:
+15.83%
1Y Performance:
+160.31%
1-Day Range:
$21.38
$22.48
1-Week Range:
$19.52
$22.48
52-Week Range:
$7.78
$35.80
Forte Biosciences Inc Stock (FBRX) Company Profile
Name
Forte Biosciences Inc
Sector
Industry
Phone
(310) 618-6994
Address
3060 PEGASUS PARK DRIVE, DALLAS, CA
Compare FBRX vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
21.94 | 442.14M | 0 | -69.38M | -51.00M | -5.2394 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Initiated | Evercore ISI | Outperform |
| Aug-18-25 | Initiated | Guggenheim | Buy |
| Jan-21-25 | Initiated | TD Cowen | Buy |
| Apr-08-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Sep-20-21 | Upgrade | Chardan Capital Markets | Sell → Buy |
| Sep-03-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Sep-03-21 | Downgrade | Chardan Capital Markets | Buy → Sell |
| Sep-03-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Sep-03-21 | Downgrade | Truist | Buy → Hold |
| May-14-21 | Initiated | B. Riley Securities | Buy |
| Mar-26-21 | Initiated | Citigroup | Buy |
| Aug-28-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-25-20 | Initiated | Truist | Buy |
View All
Forte Biosciences Inc Stock (FBRX) Latest News
Forte Biosciences Q1 2026 Earnings: Pre-revenue Biotech Misses EPS Estimates; Stock Dips on Narrower Loss MissGlobal Trading Community - Newser
FBRX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Pre-Revenue Biotech RealityLive Trade Sharing - Newser
FBRX Stock Price, Quote & Chart | FORTE BIOSCIENCES INC (NASDAQ:FBRX) - ChartMill
Forte Biosciences stock (US34960P1012): Q1 update keeps focus on skin disease pipeline - AD HOC NEWS
(FBRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Forte Biosciences Inc stock (US34960P1012): clinical pivot and cash focus keep biotech investors ale - AD HOC NEWS
Forte Biosciences (FBRX) price target increased by 19.72% to 65.02 - MSN
Forte Biosciences stock (US34960P1012): volatile biotech after recent sell-off tests investor nerves - AD HOC NEWS
Forte Biosciences stock (US34960P1012): New 13G filings highlight major holders - AD HOC NEWS
Forte Biosciences Stock: Targeting Celiac Disease (NASDAQ:FBRX) - Seeking Alpha
OrbiMed entities hold 5.8% of Forte Biosciences (FBRX), ownership split disclosed - Stock Titan
Point72 entities report 0% ownership in Forte Biosciences (FBRX) - Stock Titan
MPM BioImpact LLC takes a 7.2% position in Forte Biosciences (NASDAQ: FBRX) - Stock Titan
Alger Associates (NASDAQ: FBRX) reports 1.27M shares; 10.2% stake - Stock Titan
Janus Henderson (FBRX) discloses 9.99% holding; 299,798 pre-funded warrants - Stock Titan
Forte Biosciences (NASDAQ: FBRX) deepens Q1 loss while FB102 wins Fast Track - Stock Titan
Affinity Asset Advisors takes 7.3% stake in Forte Biosciences (NASDAQ: FBRX) - Stock Titan
Forte Biosciences stock (US34960P1012): Q1 2026 earnings report upcoming - AD HOC NEWS
Forte Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Adage (FBRX) files Schedule 13G reporting 950,000-share stake - Stock Titan
FBRX Technical Analysis | Trend, Signals & Chart Patterns | FORTE BIOSCIENCES INC (NASDAQ:FBRX) - ChartMill
Forte Biosciences stock (US34960P1012): Q1 2026 results and FDA Fast Track for FB102 - AD HOC NEWS
Chardan Capital Maintains Forte Biosciences(FBRX.US) With Buy Rating, Maintains Target Price $61 - Moomoo
MSN Money - MSN
Forte Biosciences Grants 66,667 RSUs to New Employee as Inducement - geneonline.com
New Forte Biosciences hire gets 50K options, 50K RSUs to join - Stock Titan
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - The Joplin Globe
Forte Biosciences Releases Q1 2026 Financial Results - AlphaStreet
TradingKey - TradingKey
Forte Biosciences, Inc. 1Q 2026: Net loss $(22.1M), Diluted EPS $(1.24) — 10-Q Summary - TradingView
Forte Biosciences Q1 net loss narrows as R&D spending rises - TradingView
Forte Biosciences (FBRX) widens Q1 loss and raises $172.5M to fund FB102 trials - Stock Titan
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update - The Joplin Globe
Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
FDA fast-tracks celiac treatment as Forte Biosciences raises $172M - Stock Titan
FBRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Forte Biosciences (NASDAQ:FBRX) Rating Lowered to Strong Sell at Wall Street Zen - MarketBeat
Responsive Playbooks and the FBRX Inflection - Stock Traders Daily
What Forte Biosciences (FBRX) is doing to earn customer loyalty (Breakdown Watch) 2026-05-05Wall Street Picks - newser.com
Evercore Maintains Forte Biosciences(FBRX.US) With Buy Rating, Maintains Target Price $65 - Moomoo
Wall Street Zen Upgrades Forte Biosciences (NASDAQ:FBRX) to "Sell" - MarketBeat
Stock Traders Purchase High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - MarketBeat
Forte Biosciences | DEF 14A: Definitive information statements - Moomoo
[ARS] Forte Biosciences, Inc. SEC Filing - Stock Titan
Forte Biosciences (NASDAQ: FBRX) 2026 proxy seeks approval of larger equity plan - Stock Titan
FBRX - Finviz
Is Forte Biosciences (FBRX) stock respecting technical levels | Q4 2025: Earnings Fall ShortCrowd Trend Signals - Newser
Understanding the Setup: (FBRX) and Scalable Risk - Stock Traders Daily
FBRX (Forte Biosciences Inc.) reports wider than expected Q4 2025 loss, with shares falling 3.52% following the earnings release.Financial Update - UBND thành phố Hải Phòng
Forte Biosciences Inc stock (US34960P1012): Is its immunology focus strong enough to unlock biotech - AD HOC NEWS
Forte Biosciences, Inc. (NASDAQ:FBRX) Short Interest Update - MarketBeat
Forte Biosciences Inc Stock (FBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Forte Biosciences Inc Stock (FBRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jan 01 '26 |
Option Exercise |
0.00 |
375 |
0 |
41,895 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Dec 30 '25 |
Buy |
26.33 |
9,680 |
254,833 |
41,520 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Oct 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,974 |
| Wagner Paul A. | SEE REMARKS |
Oct 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
82,190 |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Jul 01 '25 |
Option Exercise |
0.00 |
375 |
0 |
31,733 |
| Wagner Paul A. | SEE REMARKS |
Jul 01 '25 |
Option Exercise |
0.00 |
1,250 |
0 |
81,038 |
1.49%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):